[3H]Nisoxetine—A radioligand for noradrenaline reuptake sites: Correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments
Sharon C. Cheetham(RenaSci (United Kingdom)), David J. Heal(IDEXX Laboratories (France)), Jean Viggers(Critical Pharmaceuticals (United Kingdom)), Sarah Butler(Critical Pharmaceuticals (United Kingdom)), M.R. Prow(Critical Pharmaceuticals (United Kingdom))
Cited by 123
Related Papers
Amphetamine, past and present – a pharmacological and clinical perspective
|Journal of Psychopharmacology|2013|614
Experimental Approaches to Anxiety and Depression
|Behavioural Pharmacology|1993|363
Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology
|Journal of Psychopharmacology|2014|284
The pharmacology of the behavioral and hypothermic responses of rats to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)
|Psychopharmacology|1987|198
The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety
|Neuropharmacology|2009|197